Researchers testing repurposed drugs against Covid-19 found that ivermectin didn’t reduce hospital admissions, in the largest trial yet of the effect of the antiparasitic on the disease driving the pandemic. Ivermectin has received a lot of attention as a potential treatment for Covid-19 including from celebrities such as podcast host Joe Rogan. Most evidence has shown it to be ineffective against Covid-19 or has relied on data of poor quality, infectious-disease researchers said. Public-health authorities and researchers have for months said the drug hasn’t shown any benefit in treating the disease. Taking large doses of the drug is dangerous, the Food and Drug Administration has said. The latest trial, of nearly 1,400 Covid-19 patients at risk of severe disease, is the largest to show that those who received ivermectin as a treatment didn’t fare better than those who received a placebo. “There was no indication that ivermectin is clinically useful,” said Edward Mills, one of the study’s lead researchers and a professor of health sciences at Canada’s McMaster University in Hamilton, Ontario. Dr. Mills on Friday plans to present the findings, which have been accepted for publication in a major peer-reviewed medical journal, at a public forum sponsored by the National Institutes of Health. NN: This study was for low doses over 3 days. The recommended dose is according to body weight and for 10 days.